survivin siRNA nanoparticles

Survivin siRNA nanoparticles represent a class of experimental RNA interference (RNAi) therapeutics designed to silence the expression of the survivin gene (BIRC5). Survivin is a member of the inhibitor of apoptosis (IAP) protein family, which is highly overexpressed in most human malignancies but nearly absent in normal adult tissues, making it a selective target for cancer therapy. These nanoparticles utilize various delivery vehicles—such as PLGA (poly lactic-co-glycolic acid), chitosan, PAMAM dendrimers, or lipid-polymer hybrids—to protect the fragile siRNA from enzymatic degradation and facilitate its entry into tumor cells. Once internalized, the siRNA triggers the degradation of survivin mRNA, leading to reduced protein levels, induction of apoptosis, and sensitization of tumor cells to chemotherapeutic agents. Research has explored these constructs in multiple preclinical settings for malignancies including pancreatic, breast, bladder, and platinum-resistant lung cancers.

Other names

survivin siRNA-loaded nanoparticlesBIRC5 siRNA nanoparticlesBIRC-5 siRNA nanoparticlesBIRC 5 siRNA nanoparticlessiRNA-NP